Here's what we'll cover
Here's what we'll cover
If you take medication for migraines and you're also considering Wegovy for weight loss, new research may catch your attention. A study published in May 2025 found that women who started semaglutide (the active ingredient in Wegovy) reduced their use of migraine medications by roughly 8% within one year.
That's not a dramatic number on its own. But for the millions of women who manage chronic migraines alongside their weight, it points to something important: the benefits of GLP-1 medications may extend well beyond the scale.
What the Research Actually Found
The study tracked real-world prescription data for women who were newly started on semaglutide (Wegovy). Researchers compared their migraine drug use before and after starting treatment.
After 12 months, migraine medication fills had dropped by approximately 8% compared to baseline. This is an observational finding, meaning researchers tracked patterns in existing data rather than running a controlled clinical trial. That distinction matters when interpreting the results.
Still, the consistency of the signal across a large patient population is worth noting. It suggests something meaningful may be happening, not just statistical noise.
Why This Matters More for Women
Migraines disproportionately affect women. About 18% of women in the United States experience migraines, compared to roughly 6% of men, according to the American Migraine Foundation. Hormonal fluctuations, particularly around menstruation and perimenopause, are well-known migraine triggers.
The fact that this reduction appeared specifically in women is not surprising to researchers who study the overlap between metabolic health and neurological conditions. Weight and hormone levels are tightly connected, and changes in one can ripple through the other.
The Obesity-Migraine Connection
The relationship between excess weight and migraines has been studied for over two decades. People with obesity have higher rates of episodic migraine progressing to chronic migraine, meaning attacks that occur 15 or more days per month.
Several mechanisms may explain this:
- Inflammation, since adipose tissue produces inflammatory molecules called cytokines, and chronic low-grade inflammation is a known driver of migraine activity that can increase both frequency and severity of attacks
- Intracranial pressure, since increased body weight can raise pressure around the brain and spinal cord, which is associated with more frequent headaches and may contribute to the progression from episodic to chronic migraine
- Hormonal disruption, since obesity affects estrogen metabolism and estrogen fluctuations are closely tied to migraine patterns in women, particularly around menstruation and perimenopause
When weight decreases, these underlying factors may begin to normalize. That could explain why migraine medication use dropped in the study population after starting Wegovy.
How Semaglutide (Wegovy) Might Help Beyond Weight Loss
Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. Semaglutide mimics this hormone to reduce appetite, slow stomach emptying, and support significant weight loss.
But GLP-1 receptors are not only found in the gut. They're also present in the brain, including in areas involved in pain processing and inflammation regulation. Some researchers believe semaglutide may have direct effects on neurological pathways, separate from weight loss itself.
This is an active area of research. We don't yet know how much of the migraine benefit comes from weight loss versus any direct neurological effect. Both likely play a role.
What This Is Not
To be clear: Wegovy is not approved by the FDA as a migraine treatment. It is approved for chronic weight management in adults with obesity, or with overweight and at least one weight-related health condition.
The migraine reduction observed in this study is a potential secondary benefit, not a reason to start semaglutide if weight management is not part of your health picture. Your provider is the right person to evaluate whether you're an appropriate candidate.
Who Tends to See the Most Benefit
Women with both obesity and a diagnosed migraine disorder are the population most likely to see this kind of overlap in benefit. If you fit that profile, starting Wegovy for weight management may offer additional downstream effects on your headache frequency and medication burden.
The 8% reduction may sound modest, but consider what that means in practical terms. If you currently fill a migraine prescription 12 times per year, an 8% reduction means roughly one fewer prescription fill per year. Over time, with continued weight loss, that reduction may compound.
Earlier data on bariatric surgery has shown much larger reductions in migraine frequency with significant weight loss, sometimes up to 50%. Semaglutide produces meaningful but more modest weight loss than surgery, so a smaller benefit is expected.
Cost Implications Worth Thinking About
If Wegovy reduces your reliance on migraine medications, that's a real cost consideration. Migraine drugs range widely in price.
Older generic triptans (a common class of migraine abortive medications) can cost $10-$30 per month with insurance or discount programs. Newer CGRP inhibitors (calcitonin gene-related peptide blockers, a newer class of migraine preventives) can cost $600-$900 per month without coverage.
Even a modest reduction in migraine drug use could translate to real savings, especially for women on expensive CGRP inhibitors. That said, Wegovy itself carries a significant list price (around $1,350 per month without insurance), so you and your provider will need to weigh total treatment costs carefully.
For help with Wegovy costs, the GLP-1 Coupons page is a good starting point. Manufacturer savings programs through Novo Nordisk can bring out-of-pocket costs down substantially for eligible patients.
Questions to Ask Your Doctor
If you manage migraines and are considering Wegovy or another GLP-1 medication, here are specific questions to bring to your next appointment:
- Given my migraine history, would starting semaglutide be appropriate for me, and are there any factors in my neurological profile that would make it more or less suitable?
- Could weight loss affect the frequency or severity of my migraines, and what magnitude of change should I realistically expect based on how much weight I might lose?
- Are any of my current migraine medications affected by how GLP-1 drugs work, since semaglutide slows stomach emptying and that can change how quickly oral medications are absorbed?
- Should we track my migraine frequency as a secondary metric while I am on Wegovy, so we have data to evaluate whether the treatment is producing neurological benefits alongside weight loss?
- Are there any interactions between semaglutide and my CGRP inhibitor or triptan that my neurologist and prescribing provider should both be aware of?
The stomach-emptying effect is worth a specific conversation. Because semaglutide delays gastric motility (how quickly your stomach moves food and medication into the intestines), the absorption timing of oral migraine medications could theoretically be affected. Your neurologist and prescribing provider should both be in the loop.
Comparing GLP-1 Options if You're Still Deciding
If you haven't yet chosen a GLP-1 medication, it's worth knowing that Mounjaro and Ozempic (tirzepatide and semaglutide, respectively) have their own profiles and indications.
Wegovy is the semaglutide formulation specifically approved for weight management. Ozempic contains the same active ingredient but is FDA-approved for type 2 diabetes. Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors, and has shown even greater average weight loss in clinical trials.
The migraine research discussed here applies specifically to semaglutide (Wegovy). Whether tirzepatide offers similar secondary neurological benefits is not yet established in the literature.
For a side-by-side comparison of providers who can prescribe these medications, the Best Providers page on GLP-1.com lets you filter by medication, cost, and telehealth availability.
No waiting list. No insurance needed.
Frequently Asked Questions
Can Wegovy reduce migraines?
Wegovy is not approved to treat migraines, but new research suggests women who start semaglutide may use migraine medications about 8% less after one year. This is likely linked to weight loss reducing inflammation and hormonal disruption that contribute to migraines.
Why does weight loss help with migraines?
Excess body weight is associated with increased inflammation, elevated intracranial pressure, and hormonal imbalances, all of which can worsen migraine frequency and severity. Losing weight through medication or other means may help reduce these underlying triggers over time.
Does semaglutide affect how migraine medications work?
Semaglutide slows stomach emptying, which could affect how quickly oral medications are absorbed into the bloodstream. If you take oral triptans or other migraine drugs, talk to your provider about whether timing or dosing adjustments might be needed.
Is Wegovy covered by insurance for women with migraines?
Insurance coverage for Wegovy is based on its approved indication for weight management, not migraine prevention. You typically need a BMI of 30 or higher, or 27 or higher with a weight-related condition, to qualify. A migraine diagnosis alone does not typically qualify you for coverage.
How long does it take for Wegovy to potentially affect migraine frequency?
The study observed an 8% reduction in migraine drug use after one year. Meaningful weight loss on semaglutide typically begins within the first 3-6 months, so any migraine-related benefit would likely build gradually alongside weight loss progress.
Are there other GLP-1 medications that help with migraines?
The current research focuses specifically on semaglutide (Wegovy). Whether tirzepatide (Mounjaro) or other GLP-1 medications offer similar migraine benefits has not yet been established in published studies.